Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 22

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 22
---
5, and remains in effect, with respect to up to: (i) 12,500,000 Keystone Purchase Shares. As of the date of this prospectus, we have issued and sold 12,500,000 July 2025 Keystone Purchase Shares for aggregate proceeds of approximately $2,891,882 and no July 2025 Keystone Purchase Shares remain available for issuance under the July 2025 Keystone Purchase Agreement. On November 26, 2025, in order to enable us to issue and sell shares, we entered into the New Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $14,591,939 in shares of Common Stock. We do not have a right to commence any sales of Common Stock to Keystone under the New Keystone Purchase Agreement until the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the New Keystone Purchase Agreement have been satisfied, including the effectiveness of the registration statement of which this prospectus forms a part. We will control the timing and amount of any sales of Common Stock to Keystone. Actual sales of shares of Common Stock to Keystone under the Keystone Purchase Agreements will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding and our operations. Concurrent with the execution of the New Keystone Purchase Agreement, we entered into the New Keystone Registration Rights Agreement, pursuant to which we agreed to provide Keystone with customary registration rights related to the shares issued under the New Keystone Purchase Agreement. Investigational New Drug Application In July 2025, CER-1236 received an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia. In September 2025, the FDA granted Fast Track Designation to our lead investigational compound, CER-1236 for acute myeloid leukemia, which is in addition to the existing Orphan Drug Designation for the same compound. The FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides us with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis. Further, it also requires us to potentially provide expanded access to the investigational drug on an as approved basis under pre-specified conditions. 3 Nasdaq Notices of Non-compliance and Nasdaq